Setmelanotide
Setmelanotide
Setmelanotide (pronounced set-mel-an-oh-tide) is a peptide drug that is used for the treatment of certain obesity disorders. It is developed by Rhythm Pharmaceuticals and was approved by the Food and Drug Administration (FDA) in November 2020.
Etymology
The name "Setmelanotide" is derived from the drug's function. It is a melanocortin-4 receptor (MC4R) agonist, which means it stimulates the MC4R in the brain to regulate hunger and energy expenditure. The prefix "Set-" is an arbitrary designation for the drug, while "-melanotide" refers to its action on the melanocortin system.
Usage
Setmelanotide is used for the treatment of obesity and control of hunger associated with pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), and leptin receptor (LEPR) deficiency. These are all rare genetic disorders that result in severe obesity beginning at an early age.
Mechanism of Action
Setmelanotide works by activating the MC4R, a part of the brain that controls hunger and energy expenditure. By stimulating this receptor, setmelanotide can help to regulate these processes and reduce excessive hunger and obesity.
Side Effects
Common side effects of setmelanotide include injection site reactions, nausea, headache, abdominal pain, and fatigue. More serious side effects can include depression and suicidal thoughts.
Related Terms
- Peptide
- Obesity
- Rhythm Pharmaceuticals
- Food and Drug Administration
- Melanocortin-4 receptor
- Pro-opiomelanocortin
- Proprotein convertase subtilisin/kexin type 1
- Leptin receptor
- Nausea
- Headache
- Abdominal pain
- Fatigue
External links
- Medical encyclopedia article on Setmelanotide
- Wikipedia's article - Setmelanotide
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski